Nocebo effects and psychotropic drug action

Expert Review of Clinical Pharmacology

Volumn 8, Issue 2, 2015, Pages 159-161

  Amanzio, Martina ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

adverse events; expectancy theory; nocebo effect; placebo groups; randomized controlled trials

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONDITIONING; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG EFFICACY; HUMAN; INFORMATION; LEARNING; NOCEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; PROCEDURES;

ANTIDEPRESSIVE AGENTS; HUMANS; NOCEBO EFFECT; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84923373029     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.992877     Document Type: Review

References (23)

1. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Non specific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7
2. Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009;146:261-9
3. Amanzio M, Benedetti F, Vase L. A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment. Int Psychogeriatr 2012;4:1-10
4. Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses?: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85(3):283-8
5. Rief W, Nestoriuc Y, Anna von L-T, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf 2009;32:1041-56
6. Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry 2005;38:69-77
7. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol 2012;30:78-87
8. Häuser W, Bartram C, Bartram-Wunn E, Tölle T. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clin J Pain 2012;28:437-51
9. Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2012;19:672-80
10. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol 2012;259:436-47
11. Stathis P, Smpiliris M, Konitsiotis S, Mitsikostas DD. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur J Neurol 2013;20: 527-33
12. Mitsikostas DD. Nocebo in headaches: implications for clinical practice and trial design. Curr Neurol Neurosci Rep 2012;12: 132-7
13. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 2010;16:816-28
14. Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2012;19:672-80
15. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191-204
16. De la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind control trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 2010;116: 766-74
17. Amanzio M. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Recent Patents CNS Drug Discov 2011;6:41-7
18. Nestoriuc Y, Orav EJ, Liang MH, et al. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res 2010;62:791-9
19. Wolf S, Pinsky RM. Effects of placebo administration and occurrence of toxic reactions. JAMA 1954;155:339-41
20. Andrykowski M, Redd W. Longitudinal analysis of the development of anticipatory nausea. J Consult Clin Psychol 1987;55: 36-41
21. von Blanckenburg P, Schuricht F, Albert US, et al. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 2013;13:426
22. Mitsikostas DD, Deligianni CI. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation. Neurol Sci 2014. [Epub ahead of print]
23. Rief W, Glombiewski JA, Barsky AJ. General Assessment of Side Effects: GASE. Berne: Huber (electronic version). 2009. Available from: www.GASE-scale.com